Navigation Links
PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday
Date:10/9/2007

MIDLOTHIAN, Va., Oct. 9 /PRNewswire/ -- PARI Respiratory Equipment's breath-enhanced nebulizer, the PARI LC PLUS, and PRONEB Ultra compressor deliver Dey, L.P.'s new COPD medication, Perforomist Inhalation Solution, that launched nationwide yesterday. Dey, L.P. is a subsidiary of Mylan Inc. (NYSE: MYL).

Perforomist (formoterol fumarate) Inhalation Solution is indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD). Perforomist Inhalation Solution will be available through retail pharmacies, hospitals, long-term care facilities, and home healthcare companies.

"We are extremely pleased that our PARI LC PLUS nebulizer and PRONEB Ultra compressor were chosen exclusively for the clinical trials for Perforomist Inhalation Solution and are on the package insert. PARI's nebulizers and compressors are the top performers in the industry, which makes them a perfect fit for many of DEY's products -- including DuoNeb, AccuNEB, and now Perforomist," said Geoff A. Hunziker, President of PARI in the United States.

Formoterol fumarate is a rapid, long-acting beta(2)-agonist (LABA) that has been previously available in the U.S. as a dry powder formulation and has twenty years of worldwide use.

The safety and efficacy of Perforomist Inhalation Solution have been established in clinical trials when administered using the PARI LC PLUS nebulizer (with a facemask or mouthpiece) and the PARI PRONEB Ultra compressor. The safety and efficacy of Perforomist Inhalation Solution delivered from other compressor-based nebulizer combinations and non-compressor based nebulizer systems have not been established.

The PARI LC PLUS and the PRONEB Ultra are the most frequently used compressor-based nebulizer system for new nebulized medications in clinical development.

About Perforomist Inhalation Solution Indication

Perforomist Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.

Important Safety Information

Perforomist Inhalation Solution belongs to a class of medications known as long-acting beta2-adrenergic agonists (LABAs). LABAs may increase the risk of asthma-related death. Data from a large placebo-controlled US study comparing the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a LABA), the active ingredient in Perforomist Inhalation Solution.

Perforomist Inhalation Solution should not be used in patients with acutely deteriorating COPD or to treat acute symptoms. Acute symptoms should be treated with fast-acting rescue inhalers. Perforomist Inhalation Solution should not be used with other medications containing LABAs. Do not use more than one nebule twice daily. Perforomist Inhalation Solution should be used with caution in patients with cardiovascular disorders. Perforomist Inhalation Solution is not a substitute for inhaled or oral corticosteroids. The safety and efficacy of Perforomist Inhalation Solution in asthma has not been established.

In COPD clinical trials, the most common adverse events reported with Perforomist Inhalation Solution were diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, and insomnia. Please see full Prescribing Information, including Boxed Warning, at http://www.perforomist.com

About COPD

COPD refers to a number of chronic lung disorders in which the airways to the lungs become narrowed and breathing becomes progressively difficult. The most common forms of COPD are chronic bronchitis and emphysema, and many patients suffer from a combination of the two diseases.

COPD is the fourth leading cause of death in America, behind heart disease, cancer, and stroke. Twelve million Americans have been diagnosed with COPD and at least another 12 million have symptoms but are undiagnosed.

Advancements Offered by Nebulization

Perforomist Inhalation Solution is a long-acting bronchodilator that is taken by nebulizer. Of the three types of devices used to deliver bronchodilators -- nebulizers, metered-dose inhalers, and dry powder inhalers -- nebulizers require no special technique or coordination, as the liquid medication is converted into a fine mist that patients inhale through a mouthpiece or face-mask while breathing naturally. Since nebulization is an easy, effective, and thorough method of delivering medication directly into the lungs, many COPD patients ask for it, particularly as their symptoms worsen.

About Dey

Dey, L.P. is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies, and emergency care medicine. Dey, L.P. is a subsidiary of Mylan Inc. (NYSE: MYL).

About PARI Respiratory Equipment, Inc.

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them. Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufactures the award-winning PARI TREK S compact compressor, the innovative aerosol mask Bubbles the Fish II, and powerful PARI PRONEB Ultra II. PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at http://www.Pari.com

Additional information is available by contacting Ayars & Associates at 805-566-2986 or Ashley Weigand at 804-253-7274 x711.


'/>"/>
SOURCE PARI Respiratory Equipment, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. High-Throughput System Generates Ultra-Pure PCR Products Suitable for All Applications
2. Efficient Recovery of Ultrapure Plasmid DNA
3. Ultra-Fast Purification of Small Nucleic Acids
4. Inactivation of Contaminating Templates in PCR Using High Intensity Ultraviolet Light
5. Analysis of urine and seawater samples by ultrasonic nebulization with a high resolution ICP spectrometer
6. REPLI-g UltraFast Mini Kit
7. GE Healthcare leads compact ultrasound market
8. GE introduces compact ultrasound system for women
9. pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins
10. High-Titer Retroviral Vectors for Gene Delivery
11. Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Lajollacooks4u is proud to announce it has become the ... corporate cooking challenges for companies around the world, such as Illumina, HP and Qualcomm, and ... reason for its increasing popularity is due to its new team building format, a way ...
(Date:3/23/2017)... MILFORD, Mass. , March 23, 2017 ... leading partner to global in vitro diagnostics ... launch of the industry,s first multiplexed ... inherited disease testing by next-generation sequencing ... materials were developed with input from industry ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen ... the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff ... of Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, ...
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
Breaking Biology Technology:
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):